# Pizarra — PT-pseudo_41ca49bed13d (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_41ca49bed13d
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. L. Smits (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 47-year-old male
  - PSA: 14.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.734 ng/mL²
  - PSA velocity: 2.79 ng/mL/yr
  - Prior PSA: 12.0 ng/mL
  - Prostate volume: 19.07 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8159218 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 14 ng/mL. PI-RADS 4. PSAD 0.73. Prostate volume 19 mL. DRE nodus. csPCa 0.82.

Vitals: weight 89 kg, height 179 cm, BMI 27.8, BP 135/77 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Evaluation is requested after a PSA increase to 14.0 ng/mL coincides with an MRI revealing a highly suspicious lesion.

History: At 47 years of age, this mechanical engineer underwent initial PSA screening in 2022 and has since tracked his biomarkers through routine blood work. He remains a non-smoker with no regular pharmacological interventions or notable comorbid conditions. A biopsy bucket of "None" applies to his current diagnostic phase. His lifestyle includes commuter cycling five days weekly and roughly nine alcohol units per week. Although married, he resides alone, relying on his spouse for daily support. Lower urinary tract complaints dominate his current presentation, marked by an IPSS score of 27 stemming from nocturia and a diminished urinary stream that heavily disrupts his routine. He occasionally experiences mild fatigue, which he links to occupational stress and a hearing deficit requiring written consultation summaries. A knee arthroscopy performed during his thirties for athletic trauma remains an isolated past event without recent sequelae.

Physical examination: DRE: Digital assessment uncovers an asymmetrically enlarged gland harboring a firm, discrete nodule within the right mid-gland region. Abdominal and cardiovascular surveys show no abnormalities, vital parameters remain stable, and systemic pathology is absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 9 units / week; exercise Cycling 5x/week (commuter); IPSS score: 27/35 (severe LUTS).


Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.73 +/- 0.20   (95% CI 0.28-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.19  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.06  (few labelled cases resemble this one)
  - 2.8 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=0.0, psa=14.0, age=47.0, psad=0.734, dre_ord=1.0, vol=19.07, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=4, PSA=14.0, prior biopsy=None, csPCa probability=0.8159218). It failed to weigh the significant PSA velocity (2.79 ng/mL/yr), the severe LUTS (IPSS=27), and the DRE finding of a nodule, which are crucial clinical context points.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability, but the guideline criterion is conditional on the patient being biopsy-naive, which this patient is. The prior does not account for the specific PSA density (0.734 ng/mL²) or the DRE finding, which might suggest a different risk stratification than the general PI-RADS threshold alone. The prior's wide uncertainty interval (0.28-0.99) suggests the data is highly ambiguous, and the guideline's track record is based on a cohort that may not perfectly match this patient's profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context on LUTS and history
laboratory panel - full panel
guideline anchor - The guideline constrains the decision by stating that a PI-RADS $\ge 3$ lesion mandates biopsy, which is the primary factor the prior relied upon.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
Subject: Multiparametric MRI Prostate | Date: 28 Jan 2025 | Facility: Tergooi MC
FINDINGS: T2 sequences highlight a 12 mm focus of hypointensity within the right anterior mid-gland peripheral zone. High b-value DWI shows intense restricted diffusion, mirrored by corresponding ADC hypointensity.
IMPRESSION: PI-RADS 4

get_psa_trend
[{"date": "Aug 2022", "val": 2.3}, {"date": "Jun 2023", "val": 4.2}, {"date": "Apr 2024", "val": 7.7}, {"date": "Feb 2025", "val": 14.0}]

get_previous_notes
{"date": "07 Oct 2024", "author": "Dr. L. Smits (GP)", "text": "Subsequent review highlights a progressive PSA trajectory, climbing from 12.0 ng/mL recorded in April 2024 to 14.0 ng/mL on recent assays. Accompanying deterioration in lower urinary tract symptoms prompted referral for expert consultation and advanced cross-sectional imaging."}

get_lab_results
PSA: 14.0 ng/mL (26 Dec 2024, H); %Free PSA: 21% (26 Dec 2024); eGFR: >60 mL/min/1.73m2 (26 Dec 2024).

NOT RETRIEVED
The pathology report was not retrieved because the task specified that no pathology report exists on file for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- mpMRI report: PI-RADS 4 with a 12 mm focus of hypointensity and restricted diffusion.
- PSA trend: Significant rising trajectory from 7.7 ng/mL (Apr 2024) to 14.0 ng/mL (Feb 2025), with a velocity of 2.79 ng/mL/yr (from INTAKE data).
- Previous notes: Documented progressive PSA rise and LUTS prompting advanced imaging.

AGAINST Sampling this patient now:
- DRE finding: Nodus (Suspicious) is noted, but the MRI finding is the primary driver.

WHERE THIS LEANS
The evidence strongly supports proceeding with a biopsy due to the PI-RADS 4 finding on the MRI and the concerning PSA velocity, aligning with the EXPERT-PROTOCOL guideline criterion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is strongly supported by the PI-RADS 4 finding on the mpMRI, which is the primary driver for sampling in a biopsy-naive patient according to the expert protocol. This finding was confirmed by the retrieved radiology report, which detailed a 12 mm focus of hypointensity with restricted diffusion. The rising PSA trajectory, moving from 7.7 ng/mL to 14.0 ng/mL, further strengthens the indication for intervention. The statistical prior suggested biopsy, and the retrieved evidence converged with the guideline criterion.

Variables that carried weight: age=important, dre=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
